Autolus Therapeutics
AUTL
101 hedge funds and large institutions have $648M invested in Autolus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 31 increasing their positions, 37 reducing their positions, and 16 closing their positions.
5% more capital invested
Capital invested by funds: $620M → $648M (+$28.5M)
0.17% more ownership
Funds ownership: 66.97% → 67.14% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 111 → 101 (-10)
16% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 37
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
76% less call options, than puts
Call options by funds: $20K | Put options by funds: $83K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.8M |
| 3 |
JP Morgan Chase
New York
|
+$3.03M |
| 4 |
AC
Armistice Capital
New York
|
+$2.48M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SP
Syncona Portfolio
St Peter Port,
Guernsey
|
-$11.1M |
| 2 |
Morgan Stanley
New York
|
-$4.33M |
| 3 |
CC
Commodore Capital
New York
|
-$4.1M |
| 4 |
Renaissance Technologies
New York
|
-$3.57M |
| 5 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$3.2M |
AUTL Hedge Fund Activity: Q3 2024 in Review
101 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2024, worth a combined $648M — up 4.6% from $620M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AUTL and 6 opened new positions — a net loss of 10 holders — while 37 trimmed existing stakes and 31 added.
The largest buyer was Wellington Management Group, adding an estimated $25.2M. The largest seller was Syncona Portfolio, cutting an estimated $11.1M.
- 101 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2024, down from 111 in Q2 2024.
- Funds reported $648M of Autolus Therapeutics stock for Q3 2024, up 4.6% quarter-over-quarter.
- 6 funds opened new Autolus Therapeutics positions in Q3 2024 and 16 closed out, a net change of -10 holders.
- The largest Autolus Therapeutics buyer in Q3 2024 was Wellington Management Group, an estimated $25.2M added.
- The largest Autolus Therapeutics seller in Q3 2024 was Syncona Portfolio, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2024.